We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Clinical Germline Testing Evaluated for Pediatric Cancer Patients

By LabMedica International staff writers
Posted on 04 Mar 2021
Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. More...
Previous studies interrogating germline predisposition broadly across pediatric cancer types have found heritable germline predisposition in 8%–12% of patients.

The yield of germline predisposition detected is dependent on the genes included for analysis and variant interpretation as well as the ascertainment biases found in each cohort. Iterative data are required to expand upon the understanding of susceptibility to pediatric cancer and determine the extent to which germline data may translate into clinical practice.

Pediatricians and their colleagues at Memorial Sloan Kettering Cancer Center (New York, NY, USA) conducted matched tumor-normal DNA sequencing on 751 pediatric cancer patients treated at the center from July 2015 to July 2020. Tumor and blood samples were obtained and sequenced using the MSK-IMPACT platform, a capture-based NGS assay capable of identifying sequence mutations, copy number alterations and select gene fusions in 468 genes. Germline data were analyzed in 88 genes and germline pathogenic and likely pathogenic (P/LP) variants were reported. The study covered several different cancer types, including sarcoma, neuroblastoma, central nervous system (CNS) tumors, retinoblastoma, and other rare solid tumors.

The team reported that one or more P/LP variants were found in 138/751 (18%) of individuals when including variants in low-, moderate- and high-penetrance dominant or recessive genes or in 99/751 (13%) of individuals in moderate- and high-penetrance dominant genes. The found 34% of high- or moderate-penetrance variants were unexpected based on the patient’s diagnosis and previous history and 76% of patients with positive results completed a clinical genetics visit, and 21% had at least one relative undergo cascade testing as a result of this testing.

Germline variants were found in 49% of patients with retinoblastoma, 21% of patients with CNS tumors, 15% of patients with neuroblastoma, 12% of patients with sarcoma, and 19% of patients with other tumor types. The most common mutations in high- or moderate-penetrance genes were in RB1 (found in 4% of patients), NF1 (1%) and TP53 (1%) in patients with retinoblastoma and those with a prior clinical diagnoses of neurofibromatosis type 1 (NF1) - or Li Fraumeni syndrome (LFS)-associated tumors.

About 3% of patients had variants in DNA damage repair genes, 1.6 % had mutations in the RAS–MEK or mTOR–PTEN pathway, and 1% had variants in metabolic pathways related to cancer. Among genetic diseases that were not identified by MSK-IMPACT in this study was the growth disorder Beckwith–Wiedemann syndrome, identified in four patients. The authors suggested combining multiple tests in such cases, like next-generation sequencing (NGS) and RNA sequencing, to detect all types of genetic variants.

The authors noted that potential cost savings exist through cancer screening and early detection, prevention, pre-implantation genetic testing, and potentially more effective therapeutics; however, there are also significant costs associated with each of these in addition to the costs of sequencing and clinical genetics visits. The study was published on February 15, 2021 in the journal Nature Cancer.

Related Links:
Memorial Sloan Kettering Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.